Can-Fite BioPharma Ltd. CANF 深 滬
等待開盤 04-02 09:30:00 美东时间
3.079
-0.021
-0.68%
華盛通- 最 高3.21
- 今 開3.12
- 成交量 1.20万股
- 最 低 2.96
- 昨 收 3.10
- 總市值 659.69万
- 52周最高 36.40
- 市盈率 靜 --
- 換手率 0.56%
- 52周最低 2.95
- 委 比 -33.64%
- 總股本 214.25万
- 歷史最高 28380.00
- 量 比 0.45
- 振 幅 8.06%
- 歷史最低 2.96
- 每 手 1
- 風險率 7.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Can-Fite Biopharma's Veterinary Partner Vetbiolix Completes Enrollment In Phase 2 Study Of Piclidenoson For Osteoarthritis In Dogs; Topline Data Are Expected In Q3 2026
Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs associated with the registration of Piclidenoson for osteoarthritis in companion animals.Vetbiolix has exercised its option to
03-30 19:25
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Can-Fite signed a $325M deal with Vetbiolix for their veterinary arthritis drug Piclidenoson. The Phase 2 study in dogs with osteoarthritis has completed enrollment, with results expected Q3 2026. The drug, which showed success in human psoriasis, is being developed for a $3B market.
03-30 11:20
Can‑Fite BioPharma Secures Israeli Patent Allowance For A3AR Agonists, Covering Namodenoson In Obesity And Fat‑Loss Use
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics marketRamat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a
03-17 19:49
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Can-Fite BioPharma Ltd. announced that the Israeli Patent Office has allowed its patent application No. 284463, titled “An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect.” The patent covers the use of A3 adenosine receptor (A3AR) agonists, including Namodenoson, Can-Fite’s lead drug candidate, for inducing fat loss and treating obesity and related metabolic disorders. This allowance strengthens Can-Fite’s global intellectual...
03-17 11:47
Market-Moving News for March 4th
MRNA: 11% | Moderna shares are trading higher after the company announced that it has entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences. CANF: 54% | Can-Fite
03-04 20:20
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) stock rose 17.6% to $5.88 during Wednes...
03-04 20:05
Can-Fite Biopharma's Phase 2a Open-label Study Of Namodenoson For Advanced Pancreatic Ductal Adenocarcinoma Met Its Primary Endpoint
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced
03-04 20:04
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Can-Fite BioPharma Ltd. announced the immediate exercise of warrants to purchase up to 795,869 ADSs at a reduced price of $5.00 per ADS, generating approximately $4.0 million in gross proceeds. The new warrants issued to participants will allow the purchase of up to 1,591,738 ADSs at the same price, exercisable for two years. Proceeds will fund research and development, clinical trials, and general corporate purposes. The offering is expected to ...
03-04 15:25
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
Can-Fite BioPharma Ltd. announced Phase IIa study results for namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC) patients. The study met its primary safety endpoint, showing good tolerability in high-risk patients. Secondary endpoints, including overall survival (OS) and progression-free survival (PFS), are still being monitored. Namodenoson, an A3 adenosine receptor agonist, has an favorable safety profile and is also being tested f...
03-04 12:00
Can-Fite BioPharma Announces Publication Of Peer-Reviewed Study In International Journal Of Obesity Demonstrating Anti-Obesity Effect Of Namodenoson
Namodenoson's Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment MarketRamat Gan, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
02-17 20:06
